MA26836A1 - Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38. - Google Patents

Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38.

Info

Publication number
MA26836A1
MA26836A1 MA26611A MA26611A MA26836A1 MA 26836 A1 MA26836 A1 MA 26836A1 MA 26611 A MA26611 A MA 26611A MA 26611 A MA26611 A MA 26611A MA 26836 A1 MA26836 A1 MA 26836A1
Authority
MA
Morocco
Prior art keywords
protein kinase
kinase inhibitors
substituted bicyclic
nitrogen heterocycles
alkylamino substituted
Prior art date
Application number
MA26611A
Other languages
English (en)
Inventor
James Patrick Dunn
David Michael Goldstein
Ian Edward David Smith
William Harris
Teresa Rosanne Welch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26836A1 publication Critical patent/MA26836A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA26611A 1999-10-21 2002-04-19 Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38. MA26836A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16080499P 1999-10-21 1999-10-21
US21371800P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
MA26836A1 true MA26836A1 (fr) 2004-12-20

Family

ID=26857242

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26611A MA26836A1 (fr) 1999-10-21 2002-04-19 Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38.

Country Status (24)

Country Link
US (1) US6642241B1 (fr)
EP (1) EP1226144B1 (fr)
KR (1) KR100537241B1 (fr)
CN (1) CN1156477C (fr)
AR (1) AR026187A1 (fr)
AT (1) ATE349447T1 (fr)
AU (1) AU776695B2 (fr)
BR (1) BR0014973A (fr)
CA (1) CA2388140C (fr)
CO (1) CO5251408A1 (fr)
CZ (1) CZ20021743A3 (fr)
DE (1) DE60032623T2 (fr)
ES (1) ES2277858T3 (fr)
HR (1) HRP20020327A2 (fr)
HU (1) HUP0203477A3 (fr)
IL (1) IL149230A0 (fr)
MA (1) MA26836A1 (fr)
MX (1) MXPA02003841A (fr)
NO (1) NO20021783D0 (fr)
PE (1) PE20010760A1 (fr)
PL (1) PL357494A1 (fr)
TR (1) TR200201058T2 (fr)
WO (1) WO2001029041A1 (fr)
YU (1) YU29202A (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000706A (et) 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
US20040044012A1 (en) * 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
MXPA04010267A (es) * 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
KR100793688B1 (ko) * 2002-08-06 2008-01-10 에프. 호프만-라 로슈 아게 P-38 미토겐 활성 단백질 키나제 억제제로서6-알콕시-피리도-피리미딘
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
CN100497339C (zh) * 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
JP4659736B2 (ja) * 2004-04-27 2011-03-30 武田薬品工業株式会社 スクリーニング方法
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CN1984914A (zh) 2004-08-31 2007-06-20 霍夫曼-拉罗奇有限公司 7-氨基-3-苯基-二氢嘧啶并[4,5-d]嘧啶酮的酰胺衍生物、其制备和作为蛋白激酶抑制剂的应用
WO2006024486A2 (fr) 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Derives amide de 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, leur fabrication et leur utilisation en tant qu'agents pharmaceutiques
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ES2329419T3 (es) 2006-01-31 2009-11-25 F. Hoffmann-La Roche Ag 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas.
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
EP2108641A1 (fr) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3943087A1 (fr) 2013-03-15 2022-01-26 Celgene CAR LLC Composés hétéroaryle et utilisations associées
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為fgfr抑制劑之雙環雜環
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP2021501130A (ja) 2017-10-05 2021-01-14 フルクラム セラピューティクス,インコーポレイテッド DUX4の発現を低減するためのp38阻害剤の使用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP4323405A1 (fr) 2021-04-12 2024-02-21 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
PL340412A1 (en) * 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
HK1041483B (zh) 1998-10-23 2004-12-24 霍夫曼-拉罗奇有限公司 雙環氮雜環

Also Published As

Publication number Publication date
CA2388140A1 (fr) 2001-04-26
CO5251408A1 (es) 2003-02-28
HUP0203477A2 (hu) 2003-01-28
HK1051040A1 (en) 2003-07-18
JP4028236B2 (ja) 2007-12-26
NO20021783L (no) 2002-04-16
AU776695B2 (en) 2004-09-16
EP1226144A1 (fr) 2002-07-31
PE20010760A1 (es) 2001-07-21
CZ20021743A3 (cs) 2002-08-14
TR200201058T2 (tr) 2002-07-22
DE60032623T2 (de) 2007-10-11
JP2003512377A (ja) 2003-04-02
WO2001029041A1 (fr) 2001-04-26
HRP20020327A2 (en) 2004-02-29
US6642241B1 (en) 2003-11-04
AR026187A1 (es) 2003-01-29
NO20021783D0 (no) 2002-04-16
CN1382142A (zh) 2002-11-27
MXPA02003841A (es) 2002-09-30
DE60032623D1 (de) 2007-02-08
BR0014973A (pt) 2002-07-16
ES2277858T3 (es) 2007-08-01
ATE349447T1 (de) 2007-01-15
KR20020039375A (ko) 2002-05-25
IL149230A0 (en) 2002-11-10
YU29202A (sh) 2004-12-31
PL357494A1 (en) 2004-07-26
CA2388140C (fr) 2008-09-02
KR100537241B1 (ko) 2005-12-19
EP1226144B1 (fr) 2006-12-27
HUP0203477A3 (en) 2004-12-28
CN1156477C (zh) 2004-07-07
AU1137501A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
MA26836A1 (fr) Heterocycles azotes bicycliques alkylamino substitues en tant qu'inhibiteurs de kinase de proteine p38.
MA26837A1 (fr) Heterocycles azotes bicycliques heteroalky-lamino substitues en tant qu'inhibiteurs de kinase de proteine p38.
FR14C0055I2 (fr) Cyanoquinolines 3 substituees en tant qu'inhibiteurs de kinases de la proteine tyrosine
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
ATE236165T1 (de) Substituierte stickstoff enthaltende heterocyclen als p38 protein kinase inhibitoren
MA26831A1 (fr) Derives de benzodiazepine."
MA25493A1 (fr) Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
CO4910133A1 (es) Antagonistas de 5-h[1f]
MA26819A1 (fr) Pteridinones servant d' inhibiteurs de kinases.
ZA200306341B (en) Imidazo (1,2-a)-pyridine derivatives as mGluR5 antagonists.
NL300203I1 (nl) Antiviraal werkzame heterocyclische azahexaan-derivaten.
MA26932A1 (fr) Derives d'imidazole.
ATE270670T1 (de) Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
MA26824A1 (fr) 5-(2-substitué-5-hétérocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidine-7-ones servant d'inhibiteurs de phosphodiestérase.
NO20004809L (no) Trisubstituerte 1,3,5-triazinderivater for behandling av HIV- infeksjoner
IS5715A (is) Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni
BR0014775B1 (pt) misturas antimicrobianas de 1,3-bis (hidroximetil) -5,5-dimetilidantoina e 1,2-benzisotiazolin-3-ona.
FI962639A7 (fi) Diaryyli-5,6-fuusioituneita heterosyklisiä happoja leukotrieeniantagon isteina
IT1317751B1 (it) Poliolefine di metalloceni stabilizzate.
FI953104L (fi) Diaryyli-5,6-kondensoidut heterosykliset hapot leukotrieeniantagonisteina
ATE240326T1 (de) Pyrrolo-(3,2-b)pyridine und ihre verwendung als 5-ht1f agonisten
IT1313592B1 (it) Derivati di 1h-pirido 3,4-b indol-1-one.
FR11C0047I2 (fr) Acides 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-(4.3.0)-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinocarboxyliques eventuellement substitues et leurs derives
NO20014059L (no) Krystallmodifikasjon D av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo-/4.3.0/-nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre
NL194530B (nl) Takhouder, alsmede plano voor het vormen hiervan.